Paul Clarke

Team Leader

Institute of Cancer Research
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (19)

Oestrogen receptor (ER) activation leads to the formation of DNA double strand breaks (DSB), promoting genomic instability and tumour heterogeneity. The single-stranded DNA cytosine deaminase APOBEC3B (A3B) serves as a co-activator of ER and is implicated in inducing DSBs at transcriptional enhancers regulated by ER. Using whole-genome sequencing in an engineered cell model lacking base excision repair (BER) function, we demonstrate that A3B preferentially targets transcriptionally active regulatory regions in an R-loop-dependent manner. Strand-specific DNA:RNA immunoprecipitation sequencing (ssDRIP-seq) and ssDNA-associated protein immunoprecipitation sequencing (SPI-seq) confirm that A3B binds to and deaminates ssDNA within R-loops, a process facilitated by ER transactivation. Furthermore, BER-mediated processing of A3B-induced uracil bases contributes to the formation of R-loop-associated DSBs, which are essential for ER-regulated gene activation. These findings establish a role for A3B in R-loop homeostasis and transcriptional regulation, with implications for understanding ER-driven genomic instability and potential therapeutic targeting of A3B.

Year:

2026

Year:

2026

Year:

2026

Brachyury is a transcription factor that plays an essential role in tumour growth of the rare bone cancer chordoma and is implicated in other solid tumours. Brachyury is minimally expressed in healthy tissues, making it a potential therapeutic target. Unfortunately, as a ligandless transcription factor, brachyury has historically been considered undruggable. To investigate direct targeting of brachyury by small molecules, we determine the structure of human brachyury both alone and in complex with DNA. The structures provide insights into DNA binding and the context of the chordoma associated G177D variant. We use crystallographic fragment screening to identify hotspots on numerous pockets on the brachyury surface. Finally, we perform follow-up chemistry on fragment hits and describe the progression of a thiazole chemical series into binders with low µM potency. Thus we show that brachyury is ligandable and provide an example of how crystallographic fragment screening may be used to target protein classes that are difficult to address using other approaches.

Year:

2025

Purpose: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance is inevitable and includes reactivation of AR signaling. Novel therapeutic approaches targeting these mechanisms to block tumor growth is an urgent unmet clinical need. One attractive strategy is to target heat shock proteins (HSP) critical to AR functional activity. Experimental Design: We first did transcriptome analysis on multiple castration-resistant prostate cancer (CRPC) cohorts to correlate the association between the Gene Ontology cellular response to heat gene expression signature and overall survival. Next, we analyzed the impact of targeting the heat shock factor 1 (HSF1) pathway, with an inhibitor in clinical development, namely, NXP800 (formerly CCT361814), in models of treatment-resistant prostate cancer. Finally, we confirmed our mechanistic and phenotypic findings using an NXP800-resistant model and an in vivo model of CRPC. Results: We report that in multiple CRPC transcriptome cohorts, the Gene Ontology cellular response to heat gene expression signature associates with AR signaling and worse clinical outcome. We demonstrate the effects of targeting the HSF1 pathway, central to cellular stress, with an inhibitor in clinical development, namely, NXP800, in prostate cancer. Targeting the HSF1 pathway with the inhibitor NXP800 decreases HSP72 expression, activates the unfolded protein response, and inhibits AR- and E2F-mediated activity, inhibiting the growth of treatment-resistant prostate cancer models. Conclusions: Overall, NXP800 has antitumor activity against treatment-resistant prostate cancer models, including molecular subtypes with limited treatment options, supporting its consideration for prostate cancer–specific clinical development.

Year:

2025

Year:

2025

Eukaryotic translation initiation factor 4E (eIF4E) has long been recognised as a pivotal regulator of cap-dependent protein synthesis initiation. More recently, eIF4E has emerged as a multifunctional factor proposed to influence various aspects of RNA metabolism, including nuclear export of mRNA to the cytoplasm. Its versatile roles are largely attributed to its ability to bind the methyl-7-guanosine cap (m7G-cap) of mRNAs and participate in critical protein–protein interactions. Deregulated eIF4E expression or activity has been implicated in several diseases, but it is most prominently studied as an oncogene where its activity can drive cancer onset, progression and drug resistance. Consequently, eIF4E is a highly attractive target for the development of novel anti-tumour therapeutics. Recent advancements have provided new insights into the mechanism of action of eIF4E, leveraging fragment-based compound screening and genetically modified cell models to identify and characterise binding sites on this challenging-to-drug protein target. In this review, we summarise the multiple roles of eIF4E and features that underpin its activity in both the cytoplasm and nucleus, and the key findings related to the modulation of its activity and therapeutic potential.

Year:

2025

NXP800 inhibits the growth of AR-dependent and AR-independent prostate cancer models with activation of the UPR and inhibition of key signaling pathways. A and B, PDX-O [CP50, CP89, CP129, and CP142 ( A )], AR-positive (VCaP, LNCaP, LNCaP95, and 22Rv1), and AR-negative (PC3 and DU145) prostate cancer cell lines ( B ) were treated with vehicle (DMSO 0.1%) or various concentrations (5, 10, 50, 100, and 250 nmol/L) of NXP800 (active, red line), CCT365248 (inactive, blue line), and in the case of organoids, various concentrations (1 and 10 μmol/L) of enzalutamide (gray scale), and growth was determined after 5 days for cell lines and 7 days for organoids by CellTiter-Glo Cell Viability Assay as defined in “Materials and Methods.” Mean growth (compared with vehicle; defined as 1) with SD from a single experiment with three to six replicates is shown. *Abiraterone given in the castration-sensitive setting. ^CP89 and CP129 derived from two temporally separated mCRPC biopsies from the same patient. P values were calculated for NXP800 compared with CCT365248 for each concentration and for enzalutamide, compared with vehicle using the unpaired Student t test. P values ≤ 0.05 are shown (*). C–E, VCaP, LNCaP95, and 22Rv1 prostate cancer cells were treated with NXP800 (active, 100 or 250 nmol/L) or CCT365248 (inactive, 250 nmol/L) for 48 hours. RNA-seq was performed on each single experiment in triplicate (duplicate for 250 nmol/L NXP800 in LNCaP95). Analysis of RNA-seq with gene set enrichment analysis shows the enrichment and de-enrichment of Hallmark pathways in response to 100 and 250 nmol/L NXP800 (compared with 250 nmol/L CCT365248) in VCaP ( C ), LNCaP95 ( D ), and 22Rv1 ( E ) prostate cancer cells. NES and FDR are shown as volcano plots. Colored dots denote significantly (FDR 0.05) enriched (red dots) and de-enriched (blue dots) pathways with NXP800 (active compound) treatment. Table shows the NES associated with pathways wherein the FDR was ≤0.05 for 100 and/or 250 nmol/L (asterisk indicates those in which FDR was >0.05). F, VCaP ( A ), LNCaP95 ( B ), and 22Rv1 ( C ) prostate cancer cells were treated with NXP800 (active, 100 or 250 nmol/L) or CCT365248 (inactive, 250 nmol/L) for 48 hours. RNA-seq was performed on each single experiment in triplicate (duplicate for 250 nmol/L NXP800 in LNCaP95). Log 2 fold expression level changes of “activating” E2F ( E2F1 – 3 ) family members treated with NXP800 (active, 100 or 250 nmol/L) were compared with CCT365248 (inactive, 250 nmol/L). P values were calculated by DESeq2 using the Wald test. P values ≤ 0.05 are shown (*). G, VCaP, LNCaP95, and 22Rv1 prostate cancer cells were treated with 250 nmol/L CCT365248 (inactive) or 250 nmol/L NXP800 (active) for 24 hours. PERK, phospho-eIF2α, and ATF4 (PERK arm); ATF6 (ATF6 arm); IRE1 (IRE1 arm); E2F1 (E2F); and GAPDH (housekeeping) protein expression was determined by Western blot from one experiment performed in triplicate. H, Association between GO cellular response to heat gene expression signature and Hallmark E2F Targets in transcriptome cohorts of patients with PCF-SU2C and ICR-RMH. Pearson r and P values are shown.

Year:

2025

NXP800 inhibits AR transactivation and AR signaling to inhibit the growth of AR aberrant prostate cancer models. A–C, VCaP ( A ), LNCaP95 ( B ), and 22Rv1 ( C ) prostate cancer cells were treated with vehicle (DMSO 0.1%) or various concentrations (5, 10, 50, 100, and 250 nmol/L) of NXP800 (active, red line) or CCT365248 (inactive, blue line), and growth was determined after 5 days by CellTiter-Glo Luminescent Cell Viability Assay. Mean growth (compared with vehicle; defined as 1) with SD from a single experiment with six replicates is shown. P values were calculated for active compound compared with inactive compound for each concentration using the unpaired Student t test. P values ≤ 0.05 are shown (*). VCaP ( A ), LNCaP95 ( B ), and 22Rv1 ( C ) prostate cancer cells were treated with vehicle (DMSO 0.1%) or various concentrations (50, 100, and 250 nmol/L) of NXP800 (active) or CCT365248 (inactive) for 48 hours, and AR-FL, AR-V7, PSA, and GAPDH protein expression was determined from one experiment performed in triplicate. Single Western blot representative of three is shown. VCaP ( A ), LNCaP95 ( B ), and 22Rv1 ( C ) prostate cancer cells were treated with vehicle (DMSO 0.1%) or various concentrations (50, 100, and 250 nmol/L) of NXP800 (active, red line), or CCT365248 (inactive, blue line) for 48 hours, and KLK2 , KLK3 , TMPRSS2 , and FKBP5 RNA expression was determined. Mean RNA expression (normalized to average of GAPDH/B2M/HRPT1/RPLP0 and vehicle; defined as 1), with SD from a single experiment with three replicates is shown. P values were calculated for active compared with inactive compound for each concentration using the unpaired Student t test. P values ≤ 0.05 are shown (*). D, PC3 cells were transfected with CONTROL-FLAG, AR-FL-FLAG, or AR-V7-FLAG and PSA-ARE3-luciferase, prior to treatment with vehicle (DMSO 0.1%), 250 nmol/L CCT365248 (inactive), 250 nmol/L NXP800 (active), or 3 μmol/L enzalutamide for 1 hour prior to stimulation with or without 10 nmol/L DHT for 16 hours. Mean luciferase activity (compared with CONTROL-FLAG/vehicle/without DHT) with SD from two experiments with five replicates is shown. P values were calculated for each plasmid (with and without DHT stimulation) with vehicle compared with other treatments using the unpaired Student t test. P values ≤ 0.05 are shown (*). E, ChIP with an AR antibody was carried out in 22Rv1 cells that were plated in starved (charcoal-striped serum/phenol red–free) media for 72 hours prior to treatment with 250 nmol/L CCT365248 (inactive) or 250 nmol/L NXP800 (active) for 1 hour prior to stimulation with or without 10 nmol/L DHT for 5 hours. AR recruitment to AR-responsive genes ( KLK2 , KLK3 , FKBP5 , TMPRSS2 , CHRNA2 , and ANKRD30B ) was determined. Mean binding as percentage of input with SD from two experiments with three replicates is shown. P values were calculated for 250 nmol/L CCT365248 (inactive) compared with 250 nmol/L NXP800 (active) with and without DHT stimulation using the unpaired Student t test. P values ≤ 0.05 are shown (*).

Year:

2025

Purpose: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance is inevitable and includes reactivation of AR signaling. Novel therapeutic approaches targeting these mechanisms to block tumor growth is an urgent unmet clinical need. One attractive strategy is to target heat shock proteins (HSP) critical to AR functional activity. Experimental Design: We first did transcriptome analysis on multiple castration-resistant prostate cancer (CRPC) cohorts to correlate the association between the Gene Ontology cellular response to heat gene expression signature and overall survival. Next, we analyzed the impact of targeting the heat shock factor 1 (HSF1) pathway, with an inhibitor in clinical development, namely, NXP800 (formerly CCT361814), in models of treatment-resistant prostate cancer. Finally, we confirmed our mechanistic and phenotypic findings using an NXP800-resistant model and an in vivo model of CRPC. Results: We report that in multiple CRPC transcriptome cohorts, the Gene Ontology cellular response to heat gene expression signature associates with AR signaling and worse clinical outcome. We demonstrate the effects of targeting the HSF1 pathway, central to cellular stress, with an inhibitor in clinical development, namely, NXP800, in prostate cancer. Targeting the HSF1 pathway with the inhibitor NXP800 decreases HSP72 expression, activates the unfolded protein response, and inhibits AR- and E2F-mediated activity, inhibiting the growth of treatment-resistant prostate cancer models. Conclusions: Overall, NXP800 has antitumor activity against treatment-resistant prostate cancer models, including molecular subtypes with limited treatment options, supporting its consideration for prostate cancer–specific clinical development.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Collaborators (21)

Hans Oh

UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

UNITED STATES
View details

Florence Raynaud

Group Leader

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Udai Banerji

Co-Director DDU and Professor of Molecular Cancer Pharmacology

The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Ines Figueiredo

Institute of Cancer Research

UNITED KINGDOM
View details

Jyoti Choudhary

Professor of Functional Proteomics

Institute of Cancer Research

UNITED KINGDOM
View details

Adam Sharp

Team Leader

Institute of Cancer Research

UNITED KINGDOM
View details

Joseph A Newman

University of Oxford

UNITED KINGDOM
View details

Paul Workman

Harrap Professor of Pharmacology & Therapeutics

Institute of Cancer Research

UNITED KINGDOM
View details

Johann S de Bono

Head of Clinical Studies Division

Institute of Cancer Research

UNITED KINGDOM
View details

Matthew Cheeseman

Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Louisa Temme

Assistant Professor (Juniorprofessorin) of Pharmaceutical and Medicinal Chemistry

Universität Hamburg

GERMANY
View details

Simon Andrews

Head of Bioinformatics

Babraham Institute

UNITED KINGDOM
View details

Mohammad Anwar Hossain

Research Assistant Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

Benjamin Cons

Astex Pharmaceuticals

UNITED KINGDOM
View details

Chi Zhang

Research Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Peter S. Nelson

Fred Hutchinson Cancer Research Center

UNITED STATES
View details

Marissa Powers

Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Angus Lamond

Academic, Professor of Biochemistry

University of Dundee

UNITED KINGDOM
View details

Olivia Rossanese

Interim Head of Division and Head of Biology

Institute of Cancer Research

UNITED KINGDOM
View details

Caroline Ewens

Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Rahul Samant

Group Leader

Babraham Institute

UNITED KINGDOM
View details